Deven Dandekar, Ph.D., is the founder of the consulting company; Blue River Drug Development, LLC and has over 20 years of experience in toxicology as a hands-on Study Director at a Contract Research Laboratory (CRO), Bayer’s Toxicology Laboratory and as part of the Management team for a spin-off CRO divested from Bayer’s toxicology laboratory. During this time, he has designed, conducted and reported several safety assessment studies and interacted with the applicable regulatory agencies (FDA and EPA). In May 2021, Deben joined Chorus/Lilly at Lilly Headquarters in Indiana. Deven is managing all phases of the Toxicology and ADME plans for all assigned assets (internal Lilly and external assets), including creation of the preclinical safety assessment strategy, obtaining functional experts to assist in plan development, implementing the preclinical safety assessment project plan, and managing changes to the plan (timeline, budget, scope). Deven is also responsible for the toxicology/ADME plans for multiple assets in the Chorus portfolio.